Company intelligence / Profile preview

ChitogenX Inc.

Ownership: Private
Development stage: Phase 1

Overview

The company’s lead product ORTHO-R for rotator cuff tear repair has reached Phase I/II proof-of-concept clinical trials in the US. Other pipeline programs are at the preclinical stage targeting various orthopedic and musculoskeletal indications. No commercialized products yet.[2][3]

Therapeutic areas: OtherRheumatology
Modalities: Biological products (chitosan-based biopolymer matrix combined with biologics such as PRP and BMAC)[2][3]Cell replacements[3]
Industry: Biotech

Drug pipeline

1 asset

ORTHO-R

Partnerships

Polytechnique Montréal for intellectual property/licensing/grants [2]

Beyond the preview

Go deeper on ChitogenX Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChitogenX Inc..

Explore the full profile